Travere Therapeutics Inc - ESG Rating & Company Profile powered by AI
Alternative corporations in the scoring peer group for Travere Therapeutics Inc are displayed below. The Disclosure rating includes 17 UN Sustainable Development Goals including: 'Clean Water & Sanitation', 'Responsible Production & Consumption' and 'Life below Water'. Full ESG analysis of Travere Therapeutics Inc are accessed by logging in.
Travere Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.8; made up of an environmental score of 2.0, social score of 3.2 and governance score of 3.2.
2.8
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1353 | Vera Therapeutics Inc | 2.9 | Medium |
| 1353 | Veracyte Inc | 2.9 | Medium |
| 1393 | Travere Therapeutics Inc | 2.8 | Medium |
| 1393 | Bioventix PLC | 2.8 | Medium |
| 1393 | Bolt Biotherapeutics Inc | 2.8 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Travere Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Travere Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Travere Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Travere Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Travere Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Travere Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Travere Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Travere Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Travere Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Travere Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Travere Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Travere Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Travere Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Travere Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Travere Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Travere Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Travere Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Travere Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Travere Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Travere Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Travere Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Travere Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Travere Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Travere Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Travere Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Travere Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Travere Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Travere Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Travere Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Travere Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Travere Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Travere Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Travere Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Travere Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Travere Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Travere Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Travere Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.